Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

NCT03802916 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Iron Overload Due to Repeated Red Blood Cell Transfusions

Interventions

DRUG: Deferiprone DR tablets 1000 mg (Low dosage)
DRUG: Deferiprone DR tablets 1000 mg (High dosage)

Sponsor

ApoPharma